Dulaglutide vs Tirzepatide: What the Evidence Actually Shows

Step 1: Understand what each medicine is actually licensed for

Dulaglutide is a GLP-1 receptor agonist made by Eli Lilly, licensed in the UK for type 2 diabetes management. It is not licensed (and has not been evaluated by the MHRA) for weight loss in adults without diabetes. Prescribing it off-label for weight management falls outside its approved indication, which means no trial programme designed to the NICE standard for weight-loss medicines has been run for it in that context.

Tirzepatide, by contrast, received its UK weight-management licence following the SURMOUNT clinical programme. NICE formally recommended it for weight loss in December 2024 (Technology Appraisal TA1026), confirming it meets the clinical bar for adults with obesity or overweight alongside weight-related conditions. If you are exploring the tirzepatide vs dulaglutide question specifically for weight loss, the regulatory picture is decisive: one medicine has the indication, one does not.

For a broader look at how tirzepatide sits alongside other GLP-1 class medicines, the GLP-1 vs tirzepatide comparison covers that ground in detail.

Step 2: Compare the mechanisms, single agonist vs dual agonist

Dulaglutide activates one receptor: GLP-1. It mimics the gut hormone that slows gastric emptying, reduces appetite, and nudges the pancreas to release insulin after meals. That single pathway has genuine metabolic value, which is why it works well in type 2 diabetes.

Tirzepatide activates two receptors simultaneously, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). It is the only dual-agonist weight-management medicine licensed in the UK. The addition of GIP activity appears to enhance appetite suppression and energy-balance effects beyond what GLP-1 alone produces, according to the NHS medicines information for tirzepatide. This dual mechanism is one reason SURMOUNT-1 results, published in the New England Journal of Medicine, showed average body-weight reductions of around 20–21% at the 15mg maintenance dose over 72 weeks, figures that sit well above what GLP-1-only medicines have produced in comparable trial designs.

For a head-to-head between tirzepatide and liraglutide (another single GLP-1 agonist that is licensed for weight loss), the liraglutide vs tirzepatide page covers that specific comparison.

Step 3: Read the evidence side by side

Direct head-to-head trial data comparing dulaglutide and tirzepatide for weight loss does not exist, because dulaglutide has not been studied in that indication. The table below uses each medicine's own licensed-indication trial data for context, not as a like-for-like contest.

The NICE TA1026 recommendations set out the eligibility criteria for tirzepatide on the NHS, including BMI thresholds and the qualifying weight-related conditions. Private eligibility follows the licensed indication; a prescriber reviews the full clinical picture. If you are weighing up the newer pipeline molecules alongside existing options, the retatrutide vs tirzepatide page looks at what the next generation of triple agonists may offer.

Step 4: Know what comes next if tirzepatide is the right route

For adults who meet the criteria, accessing tirzepatide through a regulated private pharmacy is straightforward. At nume, the process runs: free consultation, same-day review by a GPhC-registered prescriber, identity and weight verification, then dispatch. Order before 12pm on a weekday and your pen ships that day; it arrives the next working day in a plain DPD parcel with tracking sent to your phone. The pen itself is a pre-filled KwikPen (four weekly doses per pen) stored in the fridge until use.

The Mounjaro price page sets out what a private prescription costs and what is included. Treatment pricing is also shown in full on the weight-loss treatments page. These are prescription-only medicines; the prescriber decides suitability, not the patient's preference alone. A clinical question about how tirzepatide compares to Mounjaro as a brand (they are the same medicine) is answered on the tirzepatide vs Mounjaro page.

Which medicine suits you is a clinical decision our prescribers make with you, based on your health history, current medicines, and personal circumstances. Start your free consultation to find out whether tirzepatide is appropriate for you.